Emcure Pharmaceuticals together with its subsidiary Gennova Biopharmaceuticals has signed a 22.78 MWp DC Solar Power Purchase Agreement (PPA) with Sunsure Energy, one of India's leading renewable power producers.
Through this partnership, Emcure and Gennova will receive approximately 36 million units of clean, renewable energy annually for their Pune plants. The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants with green power and offsetting 29,765.71 metric tons of CO2e annually. This agreement represents a substantial step forward in Emcure’s commitment to sustainability. Pursuant to the PPA, Emcure and Gennova have signed a Shareholders Agreement to acquire stake in Sunsure Solarpark Twelve, for the purchase of solar power under a group captive scheme as per the Electricity Act, 2023 and applicable rules thereunder.
With a strong presence in over 70 countries, Emcure Pharmaceuticals has been a trusted name in the pharmaceutical industry, consistently focusing on improving lives through innovative and quality pharmaceutical solutions. Sunsure will be supplying this power from its 150 MWp DC solar plant in Solapur, Maharashtra. This new agreement will further strengthen Emcure’s commitment to integrating sustainability across operations in its plants to minimize environmental impact.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: